XML 55 R40.htm IDEA: XBRL DOCUMENT v3.25.0.1
Stockholders' Equity (Tables)
 12 Months Ended
Dec. 31, 2024
Stockholders' Equity Note [Abstract]  
Schedule of Designated Preferred Shares As of December 31, 2024, the Company has designated the following preferred stock:
Designated Preferred SharesDecember 31, 2024
Series A4,200 
Series B2,360 
Series C590 
Series D10,000 
Series E40,000 
Series E-112,960 
Series F-124,900 
Series F-224,900 
Series F-334,860 
Series F-424,900 
Total179,670 
Schedule of Compensation Plans
The following table sets forth information as of December 31, 2024 with respect to compensation plans (including individual compensation arrangements) under which shares of common stock of the Company are authorized for issuance.
Plan category
Number of
securities to be
issued upon
exercise of
outstanding options,
warrants and rights
(a)
Weighted-average
exercise price of
outstanding
options, warrants
and rights
(b)
Number of securities
remaining available for
future issuance under
equity compensation plans
(excluding securities
reflected in column (a))
(c)
Equity compensation plans approved by security holders4,510,302$6.77 2,343,767
Equity compensation plans not approved by security holders (1)
1,256,625$8.86 255,000
Total5,766,927$7.23 2,598,767
(1)Includes (a) stock options for an aggregate of 499 shares of common stock issued under the Company’s 2019 Equity Incentive Plan, which allows for grants in the form of incentive stock options, non-qualified stock options, stock units, stock awards, stock appreciation rights, and other stock-based awards to the Company’s officers, directors, employees, consultants, and advisors, including options to purchase shares of common stock at exercise prices not less than 100% of fair value on the dates of grant. As of November 2, 2020, no additional grants may be made under this plan, which has been superseded by the Company’s 2020 Omnibus Equity Incentive Plan; however, outstanding awards granted under this plan will remain outstanding and continue to be administered in accordance with the terms of this plan and the applicable award agreements; (b) pursuant to an employment agreement dated as of August 31, 2020 between the Company and Gerard Michel, the Company’s Chief Executive Officer, on October 1, 2020, a non-qualified and non-plan stock option “inducement award” to purchase 498,000 shares of the Company’s common stock in reliance on Nasdaq Rule 5635(c)(4) pursuant to the terms of a stock option award agreement between the Company and Mr. Michel; and (c) new hire inducement awards to purchase 758,126 shares of the Company’s common stock in reliance on Nasdaq Rule 5635(c)(4) pursuant to the terms of a stock option award agreement between the Company and 27 employees hired between 2022 and 2024.
Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model
The Company values stock options using the Black-Scholes option pricing model and used the following assumptions for new grants, on a weighted average basis, during the reporting periods:
 Years Ended December 31
 20242023
Expected terms (years)
5.2 - 5.9
0.8 - 5.9
Expected volatility
98.3% -128.6%
96.4.% - 172.8%
Risk-free interest rate
3.7% - 4.7%
3.9% - 5.4%
Expected dividends0.00%0.00%
Schedule of Stock Option Activity
The following is a summary of stock option activity for the year ended December 31, 2024:
Number of Options
Weighted Average
Exercise Price Per Share
Weighted Average
Remaining
Contractual Term
(in years)
Aggregate Intrinsic
Value
 (in thousands)
Outstanding at January 1, 20244,183,232$8.17 8.3$147 
Granted2,312,0965.26 8.6
Exercised(269,673)6.24 
Expired(106,910)9.23 
Cancelled/Forfeited(351,818)5.62 
Outstanding at December 31, 20245,766,927$7.23 7.5$28,796 
Exercisable at December 31, 20243,494,864$8.35 6.5$13,947 
Unvested at December 31, 20242,272,063$5.50 8.9$14,849 
Schedule of Recognized Share-Based Compensation Cost
The following is a summary of share-based compensation expense in the statement of operations for the twelve months ended December 31, 2023 and December 31, 2024:
 Year Ended December 31,
(In thousands)20242023
Selling, general and administrative$6,690 $4,944 
Research and development2,286 2,837 
Cost of goods sold791 370 
Total$9,767 $8,151 
Schedule of Warrant Activity
The following is a summary of common stock warrant activity for the year ended December 31, 2024:
 WarrantsWeighted Average
Exercise Price
Outstanding at January 1, 20244,665,201$7.76 
Warrants issued(1)
1,612,056.01 
Warrants exercised(3,071,563)5.72 
Warrants cancelled(12,419)10.00 
Outstanding and exercisable at December 31, 20243,193,275$5.80 
(1) 1,008,102 of the warrants issued in 2024 were exercised in 2024. The remaining 603,954 warrants issued were converted to pre-funded warrants from Series E and E-1 Warrants during exercise.
The following is a summary of preferred stock warrant activity for the year ended December 31, 2024:
WarrantsWeighted Average
Exercise Price		Weighted Average
Remaining Life
(in years)
Outstanding at January 1, 202424,900$1,000 2.3
Warrants issued— — 
Warrants exercised(24,900)$1,000 
Outstanding and exercisable at December 31, 2024— $— 
Schedule of Information Related to Stock Warrants
The following table presents information related to common stock warrants at December 31, 2024:
Warrants Exercisable
Range of Exercise PricesOutstanding Number
of Warrants		Weighted Average
Remaining Warrant
Term (in years)
$0.01 (1)
1,341,375
$10.00 (2)
1,851,9000.3
3,193,275
(1) Pre-funded warrants with a $0.01 exercise price do not expire until exercised.
(2) As of February 28, 2025, 213,500 warrants were exercised with subsequent cash receipts of $2.1 million. These Series F warrants expire on May 5, 2025.